Long-term thalidomide use in refractory cutaneous lesions of systemic lupus erythematosus
Autor(a) principal: | |
---|---|
Data de Publicação: | 1998 |
Outros Autores: | , , |
Tipo de documento: | Artigo |
Idioma: | eng |
Título da fonte: | Revista da Associação Médica Brasileira (Online) |
Texto Completo: | http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0104-42301998000400007 |
Resumo: | OBJECTIVE: To evaluate the efficacy of long-term thalidomide treatment in cutaneous lesions of systemic lupus erythematosus (SLE), not responsive to conventional therapy. PATIENTS AND METHODS: Were selected 18 SLE patients (ACR criteria) with active cutaneous lesions not responsive to chloroquine, photoprotectors and low doses prednisone and who presented good response to thalidomide but relapsed after withdrawal of the drug. All female patients had no risk of pregnancy. Thalidomide was reintroduced and maintained at low dose (25-100mg/day) for a minimum of 6 months. RESULTS: Eighteen patients (16 females) with mean age of 34.2yo (16-57y.o.) received thalidomide for 6-21 months (mean 8.5m). The mean dose of prednisone at beginning of study was 38.3 mg/d and at the end was 9.7mg/d (p<0.05). Complete remission of cutaneous lesions was observed in thirteen patients (72%) and partial remission in five (28%). Side effects observed were: drowsiness in eight patients, intestinal constipation in 5, transient oliguria in 1, paresthesia of hand with normal electromyography in another one. All side effects disappeared with reduction of thalidomide dose and no patient needed to stop treatment owing to side effect. CONCLUSION: Thalidomide is a good alternative therapy to SLE patients with refractory cutaneous lesions and without any risk of pregnancy. |
id |
AMB-1_f0b029d8725c9ba7e4f50c73d7a30af4 |
---|---|
oai_identifier_str |
oai:scielo:S0104-42301998000400007 |
network_acronym_str |
AMB-1 |
network_name_str |
Revista da Associação Médica Brasileira (Online) |
repository_id_str |
|
spelling |
Long-term thalidomide use in refractory cutaneous lesions of systemic lupus erythematosusThalidomideSystemic lupus erythematosusCutaneous lesionsTreatmentOBJECTIVE: To evaluate the efficacy of long-term thalidomide treatment in cutaneous lesions of systemic lupus erythematosus (SLE), not responsive to conventional therapy. PATIENTS AND METHODS: Were selected 18 SLE patients (ACR criteria) with active cutaneous lesions not responsive to chloroquine, photoprotectors and low doses prednisone and who presented good response to thalidomide but relapsed after withdrawal of the drug. All female patients had no risk of pregnancy. Thalidomide was reintroduced and maintained at low dose (25-100mg/day) for a minimum of 6 months. RESULTS: Eighteen patients (16 females) with mean age of 34.2yo (16-57y.o.) received thalidomide for 6-21 months (mean 8.5m). The mean dose of prednisone at beginning of study was 38.3 mg/d and at the end was 9.7mg/d (p<0.05). Complete remission of cutaneous lesions was observed in thirteen patients (72%) and partial remission in five (28%). Side effects observed were: drowsiness in eight patients, intestinal constipation in 5, transient oliguria in 1, paresthesia of hand with normal electromyography in another one. All side effects disappeared with reduction of thalidomide dose and no patient needed to stop treatment owing to side effect. CONCLUSION: Thalidomide is a good alternative therapy to SLE patients with refractory cutaneous lesions and without any risk of pregnancy.Associação Médica Brasileira1998-12-01info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersiontext/htmlhttp://old.scielo.br/scielo.php?script=sci_arttext&pid=S0104-42301998000400007Revista da Associação Médica Brasileira v.44 n.4 1998reponame:Revista da Associação Médica Brasileira (Online)instname:Associação Médica Brasileira (AMB)instacron:AMB10.1590/S0104-42301998000400007info:eu-repo/semantics/openAccessSato,E. I.Assis,L. S. S.Lourenzi,V. P.Andrade,L. E. C.eng2000-07-25T00:00:00Zoai:scielo:S0104-42301998000400007Revistahttps://ramb.amb.org.br/ultimas-edicoes/#https://old.scielo.br/oai/scielo-oai.php||ramb@amb.org.br1806-92820104-4230opendoar:2000-07-25T00:00Revista da Associação Médica Brasileira (Online) - Associação Médica Brasileira (AMB)false |
dc.title.none.fl_str_mv |
Long-term thalidomide use in refractory cutaneous lesions of systemic lupus erythematosus |
title |
Long-term thalidomide use in refractory cutaneous lesions of systemic lupus erythematosus |
spellingShingle |
Long-term thalidomide use in refractory cutaneous lesions of systemic lupus erythematosus Sato,E. I. Thalidomide Systemic lupus erythematosus Cutaneous lesions Treatment |
title_short |
Long-term thalidomide use in refractory cutaneous lesions of systemic lupus erythematosus |
title_full |
Long-term thalidomide use in refractory cutaneous lesions of systemic lupus erythematosus |
title_fullStr |
Long-term thalidomide use in refractory cutaneous lesions of systemic lupus erythematosus |
title_full_unstemmed |
Long-term thalidomide use in refractory cutaneous lesions of systemic lupus erythematosus |
title_sort |
Long-term thalidomide use in refractory cutaneous lesions of systemic lupus erythematosus |
author |
Sato,E. I. |
author_facet |
Sato,E. I. Assis,L. S. S. Lourenzi,V. P. Andrade,L. E. C. |
author_role |
author |
author2 |
Assis,L. S. S. Lourenzi,V. P. Andrade,L. E. C. |
author2_role |
author author author |
dc.contributor.author.fl_str_mv |
Sato,E. I. Assis,L. S. S. Lourenzi,V. P. Andrade,L. E. C. |
dc.subject.por.fl_str_mv |
Thalidomide Systemic lupus erythematosus Cutaneous lesions Treatment |
topic |
Thalidomide Systemic lupus erythematosus Cutaneous lesions Treatment |
description |
OBJECTIVE: To evaluate the efficacy of long-term thalidomide treatment in cutaneous lesions of systemic lupus erythematosus (SLE), not responsive to conventional therapy. PATIENTS AND METHODS: Were selected 18 SLE patients (ACR criteria) with active cutaneous lesions not responsive to chloroquine, photoprotectors and low doses prednisone and who presented good response to thalidomide but relapsed after withdrawal of the drug. All female patients had no risk of pregnancy. Thalidomide was reintroduced and maintained at low dose (25-100mg/day) for a minimum of 6 months. RESULTS: Eighteen patients (16 females) with mean age of 34.2yo (16-57y.o.) received thalidomide for 6-21 months (mean 8.5m). The mean dose of prednisone at beginning of study was 38.3 mg/d and at the end was 9.7mg/d (p<0.05). Complete remission of cutaneous lesions was observed in thirteen patients (72%) and partial remission in five (28%). Side effects observed were: drowsiness in eight patients, intestinal constipation in 5, transient oliguria in 1, paresthesia of hand with normal electromyography in another one. All side effects disappeared with reduction of thalidomide dose and no patient needed to stop treatment owing to side effect. CONCLUSION: Thalidomide is a good alternative therapy to SLE patients with refractory cutaneous lesions and without any risk of pregnancy. |
publishDate |
1998 |
dc.date.none.fl_str_mv |
1998-12-01 |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article |
dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
format |
article |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0104-42301998000400007 |
url |
http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0104-42301998000400007 |
dc.language.iso.fl_str_mv |
eng |
language |
eng |
dc.relation.none.fl_str_mv |
10.1590/S0104-42301998000400007 |
dc.rights.driver.fl_str_mv |
info:eu-repo/semantics/openAccess |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
text/html |
dc.publisher.none.fl_str_mv |
Associação Médica Brasileira |
publisher.none.fl_str_mv |
Associação Médica Brasileira |
dc.source.none.fl_str_mv |
Revista da Associação Médica Brasileira v.44 n.4 1998 reponame:Revista da Associação Médica Brasileira (Online) instname:Associação Médica Brasileira (AMB) instacron:AMB |
instname_str |
Associação Médica Brasileira (AMB) |
instacron_str |
AMB |
institution |
AMB |
reponame_str |
Revista da Associação Médica Brasileira (Online) |
collection |
Revista da Associação Médica Brasileira (Online) |
repository.name.fl_str_mv |
Revista da Associação Médica Brasileira (Online) - Associação Médica Brasileira (AMB) |
repository.mail.fl_str_mv |
||ramb@amb.org.br |
_version_ |
1754212824593203200 |